Cargando…

The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer

This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yi-Kun, Wang, Xue, Hu, Nan-Lin, Yue, Jian, Si, Yi-Ran, Ju, Jie, Gao, Song-Lin, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671131/
https://www.ncbi.nlm.nih.gov/pubmed/34926260
http://dx.doi.org/10.3389/fonc.2021.759595
_version_ 1784615105575518208
author Kang, Yi-Kun
Wang, Xue
Hu, Nan-Lin
Yue, Jian
Si, Yi-Ran
Ju, Jie
Gao, Song-Lin
Yuan, Peng
author_facet Kang, Yi-Kun
Wang, Xue
Hu, Nan-Lin
Yue, Jian
Si, Yi-Ran
Ju, Jie
Gao, Song-Lin
Yuan, Peng
author_sort Kang, Yi-Kun
collection PubMed
description This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients.
format Online
Article
Text
id pubmed-8671131
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86711312021-12-16 The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer Kang, Yi-Kun Wang, Xue Hu, Nan-Lin Yue, Jian Si, Yi-Ran Ju, Jie Gao, Song-Lin Yuan, Peng Front Oncol Oncology This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients. Frontiers Media S.A. 2021-12-01 /pmc/articles/PMC8671131/ /pubmed/34926260 http://dx.doi.org/10.3389/fonc.2021.759595 Text en Copyright © 2021 Kang, Wang, Hu, Yue, Si, Ju, Gao and Yuan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kang, Yi-Kun
Wang, Xue
Hu, Nan-Lin
Yue, Jian
Si, Yi-Ran
Ju, Jie
Gao, Song-Lin
Yuan, Peng
The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title_full The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title_fullStr The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title_full_unstemmed The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title_short The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
title_sort effects of endocrine therapies on lipid profiles in chinese young women with early breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671131/
https://www.ncbi.nlm.nih.gov/pubmed/34926260
http://dx.doi.org/10.3389/fonc.2021.759595
work_keys_str_mv AT kangyikun theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT wangxue theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT hunanlin theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT yuejian theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT siyiran theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT jujie theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT gaosonglin theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT yuanpeng theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT kangyikun effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT wangxue effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT hunanlin effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT yuejian effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT siyiran effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT jujie effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT gaosonglin effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer
AT yuanpeng effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer